Skip to main content
NVDA-0.13%AAPL+0.04%GOOGL-1.07%MSFT+0.31%AMZN+0.18%TSM+1.54%SPCX+1.89%META+0.59%AVGO+0.52%TSLA+0.06%SKHY+3.45%MU+0.13%LLY+0.48%BRK-B+0.31%AMD+1.34%JPM-3.42%WMT+2.49%V-2.14%ASMLa+0.81%XOM+0.25%JNJ-0.10%INTC+1.71%0700.HK-2.28%MA-2.07%ABBV+0.32%1398.HK-0.17%ORCL+0.38%CSCO-4.50%CVX-0.61%COST+0.10%BAC-3.04%LRCX+2.87%KO+1.71%AMAT+1.77%AP2d+1.40%CAT-1.04%DELL-4.57%ARM+3.19%PG+1.46%0005.HK+0.03%HSBA.L+1.19%UNH-1.22%GE+0.07%3988.HK-0.12%MS-2.87%1816.HK-0.48%HD+2.74%NFLX-1.64%0939.HK-0.80%PM+1.47%USDCAD+0.73%CADCHF-0.69%GBPUSD-0.66%GBPCHF-0.63%USDJPY+0.58%EURUSD-0.58%CHFJPY+0.56%AUDUSD-0.53%EURCHF-0.53%AUDCHF-0.50%USDMXN+0.46%USDZAR+0.42%GBPTRY+0.41%NZDUSD-0.39%NZDCAD+0.34%USDNOK+0.34%NZDCHF-0.33%GBPHKD+0.32%USDPLN+0.31%USDSEK+0.29%GBPMXN-0.28%NZDSGD-0.28%GBPNZD-0.28%USDTHB-0.25%USDDKK+0.25%EURHKD-0.24%EURNZD-0.23%AUDSGD-0.22%NZDJPY+0.21%USDSGD+0.20%AUDCAD+0.18%EURZAR+0.18%AUDDKK-0.17%USDCNH+0.16%AUDNZD-0.16%USDILS+0.16%CADJPY-0.16%USDTRY+0.15%GBPAUD-0.12%GBPZAR+0.12%EURCAD+0.12%CHFNOK+0.12%GBPSGD-0.10%EURGBP+0.10%EURCNH-0.09%EURNOK+0.09%AUDNOK-0.08%NOKJPY-0.08%GBPJPY-0.08%EURCZK+0.08%CHFSEK+0.07%PLNJPY-0.07%GBPCAD+0.07%EURPLN+0.07%SGDJPY+0.05%EURSGD-0.05%EURSEK+0.04%AUDJPY+0.04%USDCOP-0.04%NZDMXN-0.04%USDCHF+0.02%CHFSGD-0.02%EURAUD-0.02%USDHKD-0.01%EURJPY-0.01%EURDKK0.00%XAGUSD-2.40%GAGUSD-2.40%XPTUSD-2.30%SUGAR-1.25%W1-1.17%C1-1.14%HG1-1.00%GAUUSD-0.81%XAUUSD-0.81%XNGUSD+0.74%S1-0.63%UKOIL+0.43%BTCUSD0.00%ETHUSD-0.31%USDTUSD-0.02%XRPUSD+0.27%SOLUSD-0.48%TRXUSDT+0.54%ZECUSDT+0.78%DOGEUSD+0.58%XMRUSDT-0.86%LINKUSD-0.88%XLMUSD-1.46%BCHUSDT+1.58%UNIUSD+2.06%LTCUSD+0.60%HBARUSDT-1.21%SUIUSD+0.20%TONUSD+16.86%TAOUSDT-1.01%AAVEUSD+1.40%DOTUSDT-3.41%ICPUSDT-0.30%ARBUSDT-3.27%ONDOUSDT-2.17%WLDUSDT-3.48%JUPUSDT-1.26%ATOMUSDT-1.67%INJUSDT+0.97%STXUSDT-1.85%FETUSDT-1.66%TIAUSDT-1.21%SEIUSDT-1.67%PYTHUSDT-1.32%IMXUSDT+1.00%GRTUSDT+3.54%OPUSDT+1.67%WIFUSDT-1.37%IOTAUSDT-0.04%POLUSDT+1.97%FARTCOINUSDT-3.22%AXSUSDT+0.62%EOSUSDT-0.69%DYDXUSDT-0.32%ORDIUSDT-1.68%GALAUSDT+0.23%NOTUSDT-2.88%RONINUSDT-0.79%NVDA-0.13%AAPL+0.04%GOOGL-1.07%MSFT+0.31%AMZN+0.18%TSM+1.54%SPCX+1.89%META+0.59%AVGO+0.52%TSLA+0.06%SKHY+3.45%MU+0.13%LLY+0.48%BRK-B+0.31%AMD+1.34%JPM-3.42%WMT+2.49%V-2.14%ASMLa+0.81%XOM+0.25%JNJ-0.10%INTC+1.71%0700.HK-2.28%MA-2.07%ABBV+0.32%1398.HK-0.17%ORCL+0.38%CSCO-4.50%CVX-0.61%COST+0.10%BAC-3.04%LRCX+2.87%KO+1.71%AMAT+1.77%AP2d+1.40%CAT-1.04%DELL-4.57%ARM+3.19%PG+1.46%0005.HK+0.03%HSBA.L+1.19%UNH-1.22%GE+0.07%3988.HK-0.12%MS-2.87%1816.HK-0.48%HD+2.74%NFLX-1.64%0939.HK-0.80%PM+1.47%USDCAD+0.73%CADCHF-0.69%GBPUSD-0.66%GBPCHF-0.63%USDJPY+0.58%EURUSD-0.58%CHFJPY+0.56%AUDUSD-0.53%EURCHF-0.53%AUDCHF-0.50%USDMXN+0.46%USDZAR+0.42%GBPTRY+0.41%NZDUSD-0.39%NZDCAD+0.34%USDNOK+0.34%NZDCHF-0.33%GBPHKD+0.32%USDPLN+0.31%USDSEK+0.29%GBPMXN-0.28%NZDSGD-0.28%GBPNZD-0.28%USDTHB-0.25%USDDKK+0.25%EURHKD-0.24%EURNZD-0.23%AUDSGD-0.22%NZDJPY+0.21%USDSGD+0.20%AUDCAD+0.18%EURZAR+0.18%AUDDKK-0.17%USDCNH+0.16%AUDNZD-0.16%USDILS+0.16%CADJPY-0.16%USDTRY+0.15%GBPAUD-0.12%GBPZAR+0.12%EURCAD+0.12%CHFNOK+0.12%GBPSGD-0.10%EURGBP+0.10%EURCNH-0.09%EURNOK+0.09%AUDNOK-0.08%NOKJPY-0.08%GBPJPY-0.08%EURCZK+0.08%CHFSEK+0.07%PLNJPY-0.07%GBPCAD+0.07%EURPLN+0.07%SGDJPY+0.05%EURSGD-0.05%EURSEK+0.04%AUDJPY+0.04%USDCOP-0.04%NZDMXN-0.04%USDCHF+0.02%CHFSGD-0.02%EURAUD-0.02%USDHKD-0.01%EURJPY-0.01%EURDKK0.00%XAGUSD-2.40%GAGUSD-2.40%XPTUSD-2.30%SUGAR-1.25%W1-1.17%C1-1.14%HG1-1.00%GAUUSD-0.81%XAUUSD-0.81%XNGUSD+0.74%S1-0.63%UKOIL+0.43%BTCUSD0.00%ETHUSD-0.31%USDTUSD-0.02%XRPUSD+0.27%SOLUSD-0.48%TRXUSDT+0.54%ZECUSDT+0.78%DOGEUSD+0.58%XMRUSDT-0.86%LINKUSD-0.88%XLMUSD-1.46%BCHUSDT+1.58%UNIUSD+2.06%LTCUSD+0.60%HBARUSDT-1.21%SUIUSD+0.20%TONUSD+16.86%TAOUSDT-1.01%AAVEUSD+1.40%DOTUSDT-3.41%ICPUSDT-0.30%ARBUSDT-3.27%ONDOUSDT-2.17%WLDUSDT-3.48%JUPUSDT-1.26%ATOMUSDT-1.67%INJUSDT+0.97%STXUSDT-1.85%FETUSDT-1.66%TIAUSDT-1.21%SEIUSDT-1.67%PYTHUSDT-1.32%IMXUSDT+1.00%GRTUSDT+3.54%OPUSDT+1.67%WIFUSDT-1.37%IOTAUSDT-0.04%POLUSDT+1.97%FARTCOINUSDT-3.22%AXSUSDT+0.62%EOSUSDT-0.69%DYDXUSDT-0.32%ORDIUSDT-1.68%GALAUSDT+0.23%NOTUSDT-2.88%RONINUSDT-0.79%
PB

PROCEPT BioRobotics Corporation (PRCT)

NASDAQ • Healthcare

$18.43
-$0.08 (-0.4%)
Market closed

Last close at September 22, 2026 at 20:00 UTC

Open$18.87
Day Range$18.4 - $19.2
Avg. Volume (3M)1.1M
Market Cap$1B
52 Week Range
$16.67$39.86
Next EarningsIn 41 daysNov 3, 2026

Metrics Over Time

Where the Money Goes

Q2 2026
Revenueeverything earned$94.4M100%
Gross Profitminus cost of goods$62.3M66%

In plain terms: out of every $100 in revenue, PROCEPT BioRobotics Corporation currently loses $28.

Fundamentals & Financials

Revenue (TTM)
$337.3M
Net Income (TTM)
-$109.7M
EPS (TTM)
-$1.94
ROA (TTM)
-22.9%
Current Ratio
6.55

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Earnings

-65.6%Q1 2026-$0.53
-1.8%Q2 2026-$0.56
-1.8%Q3 2026-$0.47
Next

Nov 3

in 41 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026
Miss -1.8%

PROCEPT BioRobotics’ revenue topped consensus in the second fiscal quarter of 2026, even as EPS trailed, in results reported August 4, 2026. Revenue rose 19.3% to roughly $94.5 million, up from $79.2 million a year ago, and came in at $94.5 million versus a $92.8 million estimate, +1.9%. Gross profit was about $62.4 million, with gross margin at 66.0%, while operating income was -$27.4 million and operating margin stood at -29.0%. Net income was -$26.9 million, down 37.2% from -$19.6 million a year ago, and EPS was -$0.47 versus -$0.35 a year ago; on the consensus tape, EPS of -$0.47 trailed the -$0.46 estimate (difference -$0.01). The quarter also included negative operating cash flow of roughly $57.4 million. For the next period, consensus calls for EPS of -$0.39 on revenue of $101.1 million.

View full earnings history

About PROCEPT BioRobotics Corporation

PROCEPT BioRobotics Corporation (NASDAQ: PRCT) makes urology-focused medical devices built around robotic treatment for benign prostatic hyperplasia, centered on the AquaBeam Robotic System and Aquablation therapy. The company generated $308.1 million of revenue in FY2025. Its business sits in healthcare, where it develops and sells surgical technology for minimally invasive procedures.

Name
PROCEPT BioRobotics Corporation
CEO
Larry L. Wood
Website
www.procept-biorobotics.com
Industry
Healthcare
Year Founded
2007
Employees
888

Today's Snapshot

AI-generated

PRCT closed slightly lower at 18.43, while its sector was firmer. Portnoy Law Firm, an investor law firm, announced a class action against PROCEPT BioRobotics.

Trading Volume

Below 10d avg (1.3M)

1.1M

vs S&P 500 Today

Underperforming Market

-0.57%

Updated: September 22, 2026 at 20:02 UTC

Technical Indicators

1 Buy1 Neutral6 Sell
PRCT is rated a sell as of the latest close, trading around 18.43 and remaining below its short- and medium-term moving averages while well under the long-term average. Momentum indicators are weak — RSI in the high 30s, MACD negative and CCI signaling downside — and ADX near 16 suggests limited trend conviction. Volume-based OBV is deeply negative, pointing to distribution rather than accumulation, while volatility is moderate with an ATR near 1.08. Technical takeaway: Sell — price sits below key averages with weak momentum, thin trend strength, and negative volume confirmation.
All signals
  • EMA (5 indicators)$19.56 - $25.35
    Sell
  • RSI (14)38.15
    Neutral
  • Stochastic %K (14, 3, 3)4.29
    Buy
  • MACD Level (12, 26)-0.52
    Sell

Peers & Related Assets

TWSTTwist Bioscience Corporation
$164.6-0.7%
EWTXEdgewise Therapeutics, Inc.
$44.51-0.3%
GRDNGuardian Pharmacy Services, Inc.
$44.67+1.1%
CLOVClover Health Investments, Corp.
$4.67+2.9%
INSPInspire Medical Systems, Inc.
$71.3-5.8%
AORTArtivion, Inc.
$24.13+2.1%
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.